Related Experiment Video
Updated: May 16, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
The role of mean platelet volume in metabolic dysfunction associated steatotic liver disease
Papagiouvanni Ioanna1, Nervas Vasileios2,3, Gouta Chrysoula2,4
14th Department of Internal Medicine, Hippokrateio University Hospital of Thessaloniki, Thessaloniki, Greece.
Background:
Mean platelet volume (MPV) has been reported significantly higher in patients with metabolic dysfunction associated steatotic liver disease (MASLD), suggesting a thrombogenic effect with an inconclusive link to excess risk for cardiovascular disease (CVD). The aim of this cross-sectional study was to elucidate the role of MPV in MASLD and review the literature.
Methods:
A cohort of consecutive biopsy-proven MASLD patients was retrospectively investigated for possible associations of MPV with histological features of the disease and, separately, with patients' estimated risk for CVD. CVD Risk was assessed with three different scores: QRISK2, HellenicSCORE II and NAFLD CV Risk. Laboratory investigation included calculation of insulin resistance with the Homeostasis Model Assessment (HOMA) and measurement of serum adiponectin in a subgroup of patients.
Results:
In a total of 139 MASLD patients, 56 (40.3%) with advanced fibrosis (F3/F4) steatohepatitis were included. MPV exceeded the upper limit of normal (=10 fl) in a significant proportion of study participants (n = 28.1%), with an overall mean of 9.4 ± .9 fl. Statistically significant associations of MPV with platelet count (Pearson correlation, p < .001), with fibrosis stage (one-way ANOVA, p = .040), with adiponectin (Spearman's correlation, p = .033), and all three different CVD Risk scores were found. Finally, a strong negative correlation was detected between serum adiponectin and CVD Risk scores.
Conclusions:
In this study's cohort of MASLD patients, high MPV was associated with higher fibrosis stages and with increased estimated risk for CVD. Correlations of serum adiponectin to MPV and CVD risk scores support its implication as a cytokine-mediator that has to be further studied.
Insights
High mean platelet volume (MPV) in metabolic dysfunction associated steatotic liver disease (MASLD) patients correlates with advanced fibrosis and increased cardiovascular disease (CVD) risk. Adiponectin may mediate these associations.
Area of Science:
- Hepatology
- Cardiology
- Hematology
Background:
- Elevated mean platelet volume (MPV) observed in metabolic dysfunction associated steatotic liver disease (MASLD) suggests a pro-thrombotic state.
- The link between MPV and cardiovascular disease (CVD) risk in MASLD remains unclear, necessitating further investigation.
Purpose of the Study:
- To investigate the association of MPV with histological features in biopsy-proven MASLD patients.
- To determine the relationship between MPV and estimated CVD risk using multiple scoring systems.
- To explore the role of adiponectin and insulin resistance in MASLD, MPV, and CVD risk.
Main Methods:
- Retrospective analysis of 139 biopsy-proven MASLD patients.
- Assessment of MPV, platelet count, fibrosis stage, and Homeostasis Model Assessment (HOMA) for insulin resistance.
- Calculation of CVD risk using QRISK2, HellenicSCORE II, and NAFLD CV Risk scores; measurement of serum adiponectin in a subgroup.
Main Results:
- A significant proportion of MASLD patients (28.1%) exhibited MPV above the normal limit (10 fl).
- MPV showed significant positive correlations with platelet count and fibrosis stage (F3/F4).
- MPV was significantly associated with all three CVD risk scores; serum adiponectin negatively correlated with CVD risk scores.
Conclusions:
- In MASLD patients, higher MPV is linked to advanced liver fibrosis and elevated estimated CVD risk.
- Serum adiponectin's correlation with MPV and CVD risk suggests its potential role as a cytokine mediator.
- Further research is warranted to elucidate the complex interplay between MPV, adiponectin, and CVD risk in MASLD.
Related Concept Videos
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:27Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...